A dual role for genetically modified lymphocytes in cancer immunotherapy

Vincenzo Russo, Attilio Bondanza, Fabio Ciceri, Marco Bregni, Claudio Bordignon, Catia Traversari, Chiara Bonini

Research output: Contribution to journalArticlepeer-review


T cells as the ultimate effectors of adaptive immune responses are currently used to treat patients affected by infectious diseases and certain tumors. Recently, T cells have been manipulated ex vivo with viral vectors coding for chimeric antigen receptors, exogenous T cell receptors, or 'suicide' genes to potentiate their efficacy and minimize possible side effects. However, the introduction of exogenous genes into T lymphocytes, particularly bacterial or viral transgene products, has occasionally produced immune-mediated elimination of transduced lymphocytes. This immune effect has recently been exploited in a trial of active immunotherapy in melanoma patients. In this opinion article, we discuss the therapeutic possibilities presented by the dual aspects of genetically modified lymphocytes used to treat cancer patients.

Original languageEnglish
Pages (from-to)193-200
Number of pages8
JournalTrends in Molecular Medicine
Issue number4
Publication statusPublished - Apr 2012

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine


Dive into the research topics of 'A dual role for genetically modified lymphocytes in cancer immunotherapy'. Together they form a unique fingerprint.

Cite this